Gordon Ralph Corey, MD

Professor of Medicine
Gary Hock Professor in Global Health, in the School of Medicine
Vice-Chair for Education and Global Health in the Department of Medicine
Research Professor of Global Health
Professor of Pathology
Member in the Duke Clinical Research Institute
Campus mail 310 Trent Drive Room 235 Trent, Box 90519, Durham, NC 27708
Phone (919) 668-7174
Email address corey001@mc.duke.edu

My research is based at the Duke Clinical Research Institute, a large academic clinical research organization designed to conduct clinical trials from small local studies to worldwide trials. The focus of my research is bacterial infections: complicated skin and skin structure infections; postoperative wound infections; hospital-acquired and ventilator-associated pneumonia; bacteremia; and endocarditis. Many of these trials are conducted in concert with the pharmaceutical industry in order to register new antibiotics. In addition, as director of infectious diseases at the DCRI I oversee the work of the mycology group, and tuberculosis trials. This work also includes work supported by NIH grants including sepsis trials, the Staph Aureus and Staph Epi Bacteremia Groups, and the International Collaboration of Endocarditis. The team of investigators with whom I work is highly experienced, amazingly productive and wonderfully collegial.

As a result of my longstanding interest in tropical medicine and the generosity of my patients as well as the Hubert Family we have been able to establish the Hubert-Yeargan Center for Global Health. As a result we have developed a medical center-wide fellowship in Global Health. I am presently the Director of the Center and the Gary Hock Distinguished Professor of Global Health.

Education and Training

  • Fellowship, Infectious Diseases, Duke University School of Medicine, 1978 - 1980
  • Chief Resident, General Internal Medicine, Duke University School of Medicine, 1977 - 1978
  • Residency, General Internal Medicine, Duke University School of Medicine, 1975 - 1977
  • Internship, General Internal Medicine, Duke University School of Medicine, 1974 - 1975
  • M.D., Baylor University, 1973

Publications

Corey, GR, Good, S, Jiang, H, Moeck, G, Wikler, M, Green, S, Manos, P, Keech, R, Singh, R, Heller, B, Bubnova, N, O'Riordan, W, and SOLO II Investigators, . "Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 60, no. 2 (January 2015): 254-262.

PMID
25294250
Full Text

Durkin, MJ, and Corey, GR. "New developments in the management of severe skin and deep skin structure infections - focus on tedizolid." Therapeutics and clinical risk management 11 (January 2015): 857-862. (Review)

PMID
26045667
Full Text

Corey, R, Naderer, OJ, O'Riordan, WD, Dumont, E, Jones, LS, Kurtinecz, M, and Zhu, JZ. "Safety, tolerability, and efficacy of GSK1322322 in the treatment of acute bacterial skin and skin structure infections." Antimicrobial agents and chemotherapy 58, no. 11 (November 2014): 6518-6527.

PMID
25136015
Full Text

Corey, GR, Jiang, H, and Moeck, G. "Dalbavancin or oritavancin for skin infections." The New England journal of medicine 371, no. 12 (September 2014): 1162-1163. (Letter)

PMID
25243251
Scholars@Duke

Moran, GJ, Fang, E, Corey, GR, Das, AF, De Anda, C, and Prokocimer, P. "Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial." The Lancet. Infectious diseases 14, no. 8 (August 2014): 696-705.

PMID
24909499
Full Text

Corey, GR, Kollef, MH, Shorr, AF, Rubinstein, E, Stryjewski, ME, Hopkins, A, and Barriere, SL. "Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival." Antimicrobial agents and chemotherapy 58, no. 6 (June 2014): 3581-.

PMID
24829393
Full Text

Corey, GR, Kabler, H, Mehra, P, Gupta, S, Overcash, JS, Porwal, A, Giordano, P, Lucasti, C, Perez, A, Good, S, Jiang, H, Moeck, G, O'Riordan, W, and SOLO I Investigators, . "Single-dose oritavancin in the treatment of acute bacterial skin infections." The New England journal of medicine 370, no. 23 (June 2014): 2180-2190.

PMID
24897083
Full Text

Stryjewski, ME, Lentnek, A, O'Riordan, W, Pullman, J, Tambyah, PA, Miró, JM, Fowler, VG, Barriere, SL, Kitt, MM, and Corey, GR. "A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study." BMC infectious diseases 14 (May 23, 2014): 289-.

PMID
24884578
Full Text

Barriere, SL, Stryjewski, ME, Corey, GR, Genter, FC, and Rubinstein, E. "Effect of vancomycin serum trough levels on outcomes in patients with nosocomial pneumonia due to Staphylococcus aureus: a retrospective, post hoc, subgroup analysis of the Phase 3 ATTAIN studies." BMC infectious diseases 14 (April 4, 2014): 183-.

PMID
24708675
Full Text

Torres, A, Rubinstein, E, Corey, GR, Stryjewski, ME, and Barriere, SL. "Analysis of Phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure." The Journal of antimicrobial chemotherapy 69, no. 4 (April 2014): 1119-1126.

PMID
24398339
Full Text

Pages